$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

The Potential Anti-HBV Effect of Amantadine in Combination with Ursodeoxycholic Acid and Biphenyl Dimethyl Dicarboxylate in HepG2 2.2.15 Cells

Abstract

Experimental studies have demonstrated that the triple combination of amantadine (A)/ ursodeoxycholic acid (UDCA, U)/ biphenyl dimethyl dicarboxylate (DDB, D) might have a preferential antiviral effect compared with that observed in interferon-induced antiviral signal pathways, such as those of $STAT1\alpha$ and the 6-16 genes. To confirm the results, this study examined whether th signal transduction for the antiviral activity in HepG2 2.2.15 was induced dependently or independently of interferon. To accomplish this, the correlation between the $STAT1\alpha$ and 6-16 genes, and nitric oxide, for the mediation of the antiviral activity was assessed. The increase in nitric oxide in the UDCA groups suggests that the inhibition of viral gene replication was enhanced by the amantadine combinations (AU and AUD), and might be more effective if incubated for longer periods. It was found that $STAT1\alpha$ was activated by the amantadine combination, although to a lesser extent than that of $interferon-\alpha$, and the primary endpoints examined for the inhibition of gene expression (HBsAg and HBcAg) were remarkably well regulated. This suggests that the amantadine triple, or at least the double, combination had better clinical benefits than those of $IFN-\alpha$ and the nucleoside analogue single treatment. This demonstrates that the amantadine combination might be a substitute for the existing HBV therapy if the results of in vivo and in vitro studies concur.

저자의 다른 논문

참고문헌 (28)

  1. Asmuth, D. M., Nguyen, H. H., Melcher, G. P., Cohen, S. H., and Pollar, R. B., Treatments for hepatitis B. Clin. Infect. Dis., 39, 1353-1362 (2004) 
  2. Beasley, R. P., Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer, 61, 1942-1956 (1988) 
  3. Davey, S., State of the world's vaccines and immunization. Geneva: World Health Organisation, 76-82 (1996) 
  4. Guidotti, L. G.., McClary, H., Loudis, J. M., and Chisari, F. V., Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J. Exp. Med., 191, 1247-1252 (2000) 
  5. Hancke, J. L., Burgos, R., and Ahumada F., Schisandra chinensis (Turcz) Baill. Fitotherapia, 70, 451-471 (1999) 
  6. Neuman, M. G., Blendis, L. M., Shear, N. H., Malkiewicz, I. M., Ibrahim, A., Katz, G. G., Sapir, D., Halpern, Z., Brill, S., Peretz, H., Magazinik, S. M., and Konikoff, F. M., Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy inth interferon alpha, ribavirin, and ursodeoxycholate. Clin. Biochem., 34, 183-188 (2001) 
  7. Reiss, C. S. and Komatsu, T., Does nitric oxide play a critical role in viral infection?, J. Virol., 72, 4547-4551 (1998) 
  8. Stuyver, L. J., Lostia, S., and Adams, M. et al. Antiviral activities and cellular toxicities of modified 2,3-dideoxy-2,3-Didehydrocytidine analogues. Antimicrob. Agents Chemother., 3854-3860 (2002) 
  9. Chiu, P. Y., Tang, M. H., Mak, D. H. F., Poon, M. K. T., and Ko, K. M., Hepatoprotective mechanism of schsandrin B: Role of mitochondrial glutathione antioxidant status and heat shock proteins. Free Radical Res., 35, 368-380 (2003) 
  10. Sells, M. A. and Chen, M. L., Acs, G.., Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. U.S.A., 84, 1005-1009 (1987) 
  11. Locarnini, S. and Birch, C., Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIVinfected patients. J. Hepatol., 30, 536-550 (1999) 
  12. Cotonat, T., Quiroga, J. A., Lopez-Alcorocho, J. M., Clouet, R., Pardo, M., Manzarbeitia, F., and Carreno, V., Piolt study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. Hepatology, 31, 502-506 (2000) 
  13. Platania, L. C. and Fish, E. N., Signaling pathways activated by interferons. Exp. Hematol., 27, 1583-1592 (1999) 
  14. Bonkovsky, H. L., Therapy of hepatitis C: Other options. Hepatology, 26, S143-151 (1997) 
  15. Clercq, E. D., Perspectives for the treatment of hepatitis B virus infections. Int. J. Antimicrob. Ag., 12, 81-95 (1999) 
  16. Wharton, S. A., Belshe, R. B., Skehel, J. J., and Hay, A. J., Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J. Gen. Virol., 75, 945-948 (1994) 
  17. Darnell, J. E. Jr., Kerr, I. M., and Stark, G. R., Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264, 1415-1421 (1994) 
  18. Findor, J. A., Daruich, J. Z., and Bruch, I. E., Amantadine HCl alone and associated with recombinant alpha IFN 2a during a short term therapy in chronic HCV infection. Hepatology, 26:217A (1997) 
  19. Bose, S., Kar, N., Maitra, R., Didonato, J. A., and Banerjee, A. K., Temporal activation of $NF-\kappaB$ regulates an interferonindependent innate antiviral response against cytoplasmic RNA viruses. Proc. Natl. Acad. Sci. U.S.A., 100, 10890-10895 (2003) 
  20. Lindenmann, J., From interference to interferon: a brief historical introduction. Philos. T. Roy. Soc. B., 299, 3-6 (1982) 
  21. Zhu, H., Zhao, H., Collins, C. D., Eckenrode, S. E., Run, Q., McIndoe, R. A., Crawford, J. M., Nelson, D. R., She, J. X., and Liu1, C., Gene expression association with interferon alpha antiviral activity in an HCV replicon cell line. Hepatology, 37, 1180-1188 (2003) 
  22. Fabris, P., Tositti, G.., Mazzella, G.., Zanetti, A. R., Nicolin, R., Pellizzer, G., Benedetti, P., and de Lalla, F., Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment. Pharm. Ther., 13, 1187- 1193 (1999) 
  23. Clercq, E. D., Antivirals and antiviral strategies. Nat. Rev. Microbiol., 2, 704-720 (2004) 
  24. Huber, R., Hockenjos, B., and Blum, H. E., DDB treatment of patients with chronic hepatitis. Hepatology, 39, 1732-1733 (2004) 
  25. Abdelmalek, M. F., Harrison, M. E., Gross, Jr. J. B., Poterucha, J. J., Gossard, A. A., Spivey, J. R., Rakela, J., and Lindor, K. D., Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. J. Clin. Gastroenterol, 26, 130-134 (1998) 
  26. Koulentaki, M., Notas, G., Petinaki, E. Valatas, V., Mouzas, I. A., Castanas, E., and Kouroumalis, E. A., Nitric oxide and proinflammatory cytokines in acute hepatitis B. Eur. J. Int. Med., 15, 35-38 (2004) 
  27. Lowenstein, C. S., Dinerman, J. L., and Snyder, S. H., Nitric oxide: a physiologic messenger. Ann. Intern. Med., 120, 227- 237 (1994) 
  28. Trauner, M. and Graziadel, I. W., Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment. Pharmacol. Ther., 13, 979-995 (1999) 

이 논문을 인용한 문헌 (2)

  1. 2006. "" Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea, 29(5): 405~411 
  2. Joo, Seong-Soo ; Chin, Hyouk-Jun ; Won, Tae-Joon ; Jang, Su-Kil ; Hwang, Kwang-Woo ; Lee, Do-Ik 2007. "Hepatoprotective and a Potential Antiviral Effect of Biphenyl Dimethyl Dicarboxylate/Amantadine for an Acute Viral Hepatitis Induced by MHV-2 in ICR Mice" 약학회지 = Yakhak hoeji, 51(3): 194~198 

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

이 논문과 연관된 기능

DOI 인용 스타일